Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Asset Writedowns and Impairment (2019 - 2024)

Ani Pharmaceuticals' Asset Writedowns and Impairment history spans 6 years, with the latest figure at $7.6 million for Q4 2024.

  • For Q4 2024, Asset Writedowns and Impairment changed N/A year-over-year to $7.6 million; the TTM value through Dec 2025 reached $7.6 million, changed 0.0%, while the annual FY2025 figure was $767000.0, 89.91% down from the prior year.
  • Asset Writedowns and Impairment for Q4 2024 was $7.6 million at Ani Pharmaceuticals, up from -$1000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $7.6 million in Q4 2024 and bottomed at -$1000.0 in Q3 2022.
  • The 4-year median for Asset Writedowns and Impairment is $341000.0 (2020), against an average of $2.1 million.
  • The largest annual shift saw Asset Writedowns and Impairment skyrocketed 354.67% in 2020 before it skyrocketed 596.19% in 2021.
  • A 4-year view of Asset Writedowns and Impairment shows it stood at $341000.0 in 2020, then surged by 596.19% to $2.4 million in 2021, then crashed by 100.04% to -$1000.0 in 2022, then surged by 760100.0% to $7.6 million in 2024.
  • Per Business Quant, the three most recent readings for ANIP's Asset Writedowns and Impairment are $7.6 million (Q4 2024), -$1000.0 (Q3 2022), and $2.4 million (Q4 2021).